Lyra Therapeutics Appoints New Directors, Adjusts Executive Pay
Ticker: LYRA · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, personnel
TL;DR
Lyra Therapeutics adds two directors and revises exec pay. New faces, new terms.
AI Summary
Lyra Therapeutics, Inc. announced on December 12, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Jonathan M. Rothberg and Mr. David E. R. Johnson, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Ms. Marie-Louise de la Chapelle, and its Chief Financial Officer, Mr. Michael J. Wilson, effective December 12, 2024.
Why It Matters
The appointment of new directors and adjustments to executive compensation can signal strategic shifts or confidence in the company's future direction, impacting investor perception.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect future strategy and performance.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Rothberg (person) — Newly elected Director
- Mr. David E. R. Johnson (person) — Newly elected Director
- Ms. Marie-Louise de la Chapelle (person) — Chief Executive Officer
- Mr. Michael J. Wilson (person) — Chief Financial Officer
FAQ
Who were the new directors elected to Lyra Therapeutics' Board?
Dr. Jonathan M. Rothberg and Mr. David E. R. Johnson were elected as new directors to Lyra Therapeutics' Board of Directors.
When were the new director appointments and executive compensation changes effective?
The changes were effective as of December 12, 2024.
What positions do the newly appointed directors hold within the company?
The filing states they were elected to the Board of Directors; their specific roles on committees are not detailed in this section.
Are the details of the new executive employment agreements provided in this filing?
This filing indicates that new employment agreements were entered into, but the specific terms and details of these agreements are not fully disclosed within this 8-K report.
What is Lyra Therapeutics' primary business?
Lyra Therapeutics, Inc. is in the business of Surgical & Medical Instruments & Apparatus, as indicated by its SIC code 3841.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-12-13 17:06:52
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
Filing Documents
- d888261d8k.htm (8-K) — 23KB
- 0001193125-24-278688.txt ( ) — 143KB
- lyra-20241212.xsd (EX-101.SCH) — 3KB
- lyra-20241212_lab.xml (EX-101.LAB) — 18KB
- lyra-20241212_pre.xml (EX-101.PRE) — 11KB
- d888261d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 13, 2024 Lyra Therapeutics, Inc. By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer